Lymphoblastic Lymphoma in Childhood and Adolescence. (1st September 2013)

• Record Type: Journal Article
• Authors: Schmidt, Eva; Burkhardt, Birgit
• Is Part Of: Pediatric hematology and oncology. Volume 30:Number 6(2013:Sep.)
• Page Start: 484
• Page End: 508
• Publication Date: 2013-09-01
• Subjects: Pediatric hematology -- Periodicals; Tumors in children -- Periodicals; Blood -- Diseases -- Periodicals; Hematologic Diseases -- Child; Hematologic Diseases -- Infant; Neoplasms -- Child; 618.9215
• DOI: 10.3109/08880018.2013.789574
• Languages: English
• ISSNs: 0888-0018

Abstract

<abstract> <title> <x xml:space="preserve">Abstract</x> </title> <p>Lymphoblastic lymphoma (LBL) are thought to derive from immature precursor T-cells or B-cells. LBL are the second most common subtype of Non-Hodgkin Lymphoma (NHL) in children and adolescents. LBL are closely related to acute lymphoblastic leukemia (ALL), the most common type of cancer in children. Using ALL-type treatment regimen to treat children with LBL was an important development in the treatment of LBL. During the last decades, several systematic clinical trials contributed to the controlled optimization of treatment. Today event-free survival (EFS) can be achieved for 75–90% of patients. However, acute and long-term toxicity, the lack of prognostic parameters and the poor outcome for patients who suffer from refractory or relapsed LBL remain highly relevant subjects for improvement. To date, the pathogenesis of LBL is poorly understood. Learning more about the biology and pathogenesis of LBL might pave the way for targeted treatment to improve survival especially in relapsed and refractory patients.</p> </abstract>